ACIXF (Acarix AB) Total Long-Term Assets: $0.65 Mil (As of Mar. 2026)


ACIXF Acarix AB ACIXF
44 GF Score
Price $0.03
GF Value $0.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Acarix AB Total Long-Term Assets?

Acarix AB ACIXF 44 Total Long-Term Assets is $0.65 Mil as of Mar. 2026. GuruFocus rates ACIXF with a GF Score™ of 44/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Acarix AB's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $0.65 Mil.

Acarix AB Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Acarix AB's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB Total Long-Term Assets Chart

Acarix AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.86 1.52 1.23 0.92 0.74

Acarix AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.88 0.83 0.74 0.65
ACIXF
44GF Score
Acarix AB ACIXF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $0.65 Mil mean?
Acarix AB (ACIXF) has a Total Long-Term Assets of $0.65 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Acarix AB and its competitors.
Is Acarix AB's Total Long-Term Assets too high?
Acarix AB's current Total Long-Term Assets is $0.65 Mil. Overall, Acarix AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Total Long-Term Assets compare to ABT and SYK?
Acarix AB's Total Long-Term Assets of $0.65 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Acarix AB and its competitors. Acarix AB's current Total Long-Term Assets is $0.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 44.4% above its estimated fair value. The current Total Long-Term Assets is $0.65 Mil. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Total Long-Term Assets is $0.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (ACIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of $0.03 is trading 44.4% above its estimated GF Value™ of $0.02. GuruFocus considers Acarix AB to be Significantly Overvalued.

Key valuation signals for ACIXF:

  • Total Long-Term Assets: $0.65 Mil
  • GF Value™: $0.02 vs. price of $0.03 (44.4% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acarix AB Business Description

Other Exchanges ACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score

Get the complete analysis for ACIXF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price
$0.02
GF Value